[HTML][HTML] Gefitinib plus celecoxib in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group
A Agarwala, W Fisher, D Bruetman, J McClean… - Journal of Thoracic …, 2008 - Elsevier
Background Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) pathway,
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
[PDF][PDF] Gefitinib Plus Celecoxib in Chemotherapy-Naıve Patients with Stage IIIB/IV Non-small Cell Lung Cancer
A Agarwala, W Fisher, D Bruetman, J McClean… - Journal of Thoracic …, 2008 - core.ac.uk
Background: Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) pathway,
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
[PDF][PDF] Gefitinib Plus Celecoxib in Chemotherapy-Naıve Patients with Stage IIIB/IV Non-small Cell Lung Cancer
A Agarwala, W Fisher, D Bruetman… - Journal of Thoracic …, 2008 - academia.edu
Background: Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) pathway,
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
[PDF][PDF] Gefitinib Plus Celecoxib in Chemotherapy-Naıve Patients with Stage IIIB/IV Non-small Cell Lung Cancer
A Agarwala, W Fisher, D Bruetman… - Journal of Thoracic …, 2008 - scholar.archive.org
Background: Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) pathway,
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
A Agarwala, W Fisher, D Bruetman… - Journal of Thoracic …, 2008 - europepmc.org
Background Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) pathway,
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
Gefitinib Plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group
A Agarwala, W Fisher, D Bruetman, J McClean… - Journal of Thoracic …, 2008 - jto.org
Background Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) pathway,
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group
A Agarwala, W Fisher, D Bruetman… - Journal of thoracic …, 2008 - pubmed.ncbi.nlm.nih.gov
Background Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) pathway,
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …